High-Dose Vitamin D Significantly Reduces Disease Activity in Early MS Onset: Clinical Trial

A French study published in JAMA found that 100,000 IU of oral cholecalciferol every two weeks significantly reduced disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. The randomized controlled trial of 316 participants showed a significantly lower rate of disease activity in the high-dose vitamin D group compared to the placebo group. This research supports vitamin D as a potentially inexpensive and well-tolerated treatment option, especially in areas with limited access to standard therapies.
Read more